Product logins

Find logins to all Clarivate products below.


Epilepsy is a heterogeneous condition requiring individualized treatment, based largely on a patient’s seizure syndrome and seizure type. Epilepsy patients also differ widely in their responses to treatment with antiepileptic drugs (AEDs) and often are treatment-refractory. As a result, neurologists must consider many factors when selecting among the numerous first-, second-, and third-generation AEDs currently available, and make adjustments—in dosing, or by adding and switching—throughout a patients’ disease course to achieve optimal seizure control. Understanding the many decision points neurologists face in the treatment of epilepsy provides important context about the complex market that developers of investigational AEDs will enter.

How is epilepsy being treated in the United States today, and what are the factors behind those treatment decisions? The Epilepsy Current Treatment Overview provides a synopsis of current treatment goals, key therapies, and medical practice in the G7 markets. The detailed, expanded analysis in Epilepsy Current Treatment (US) offers a snapshot of how U.S. neurologists are currently managing their epilepsy patients as well as insight into the factors driving such prescribing habits. This new Current Treatment offering provides deep insights, with real-world evidence wherever possible.

Related Market Assessment Reports

Report
Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by…
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Biosimilars – Current Treatment – Immunology
Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity to…
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine…